Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis. METHODS: In two randomized, placebo-controlled, phase 3 trials of identical design (SOLO 1 and SOLO 2), we enrolled adults with moderate-to-severe atopic dermatitis whose disease was inadequately controlled by topical treatment. Patients were randomly assigned in a 1:1:1 ratio to receive, for 16 weeks, subcutaneous dupilumab (300 mg) or placebo weekly or the same dose of dupilumab every other week alternating with placebo. The primary outcome was the proportion of patients who had both a score of 0 or 1 (clear or almost clear) on the Investigator's Global Assessment and a reduction of 2 points or more in that score from baseline at week 16. RESULTS: We enrolled 671 patients in SOLO 1 and 708 in SOLO 2. In SOLO 1, the primary outcome occurred in 85 patients (38%) who received dupilumab every other week and in 83 (37%) who received dupilumab weekly, as compared with 23 (10%) who received placebo (P<0.001 for both comparisons with placebo). The results were similar in SOLO 2, with the primary outcome occurring in 84 patients (36%) who received dupilumab every other week and in 87 (36%) who received dupilumab weekly, as compared with 20 (8%) who received placebo (P<0.001 for both comparisons). In addition, in the two trials, an improvement from baseline to week 16 of at least 75% on the Eczema Area and Severity Index was reported in significantly more patients who received each regimen of dupilumab than in patients who received placebo (P<0.001 for all comparisons). Dupilumab was also associated with improvement in other clinical end points, including reduction in pruritus and symptoms of anxiety or depression and improvement in quality of life. Injection-site reactions and conjunctivitis were more frequent in the dupilumab groups than in the placebo groups. CONCLUSIONS: In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo. Trials of longer duration are needed to assess the long-term effectiveness and safety of dupilumab. (Funded by Sanofi and Regeneron Pharmaceuticals; SOLO 1 ClinicalTrials.gov number, NCT02277743 ; SOLO 2 ClinicalTrials.gov number, NCT02277769 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As neurons express receptors for IL-4 and IL-13, the early improvement of itch upon targeted therapy with dupilumab, tralokinumab or lebrikizumab supports the assumption of a direct effect of these drugs on nerve endings92,96,183.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [183]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two phase 3 trials found dupilumab to significantly improve symptoms and quality of life in patients with AD compared to placebo [39].”
From Atopic dermatitis (2018) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“Upadacitinib, a JAK inhibitor with proven efficacy in moderate-tosevere AD 30,31 , and dupilumab, an IL-4Rα antagonist that blocks IL-4/IL-13 signalling 32,33 , were selected.”
From Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
Self-citationDupilumab in Persistent Asthma with Elevated Eosinophil Levels
Wenzel, S., Ford, L., Pearlman, D., Spector, S., Sher, L., Skobieranda, F., Wang, L., Kirkesseli, S., Rocklin, R., Bock, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304048 · Cited by 1,320
Self-citationGuidelines of care for the management of atopic dermatitis
Eichenfield, L. F., Tom, W. L., Berger, T. G., Krol, A., Paller, A. S., Schwarzenberger, K., Bergman, J. N., Chamlin, S. L., Cohen, D. E., Cooper, K. D., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.023 · Cited by 1,224
Self-citationThe eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, J. M., Thurston, M., Omoto, M., Cherill, R., Tofte, S. J., Graeber, M., & Evaluator Group, T. E. (2001) · Experimental Dermatology · doi:10.1034/j.1600-0625.2001.100102.x · Cited by 1,200
Atopic dermatitis: a disease of altered skin barrier and immune dysregulation
Boguniewicz, M., & Leung, D. Y. M. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01027.x · Cited by 1,073
Wenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationGittler, J. K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K. J., Wang, C. Q. F., Mitsui, H., Cardinale, I., de Guzman Strong, C., Krueger, J. G., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.012 · Cited by 981
Self-citation
Cited by
Items 101–200 of 1,002
The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype
Leung, D. Y. M., Calatroni, A., Zaramela, L. S., LeBeau, P. K., Dyjack, N., Brar, K., David, G., Johnson, K., Leung, S., Ramirez-Gama, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav2685 · Cited by 214
Faiz, S., Giovannelli, J., Podevin, C., Jachiet, M., Bouaziz, J.-D., Reguiai, Z., Nosbaum, A., Lasek, A., Ferrier le Bouedec, M.-C., Du Thanh, A., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.053 · Cited by 210
Self-citationInterleukin-33 in atopic dermatitis
Imai, Y. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.08.006 · Cited by 209
Immortalized N/TERT keratinocytes as an alternative cell source in 3D human epidermal models
Smits, J. P. H., Niehues, H., Rikken, G., van Vlijmen-Willems, I. M. J. J., van de Zande, G. W. H. J. F., Zeeuwen, P. L. J. M., Schalkwijk, J., & van den Bogaard, E. H. (2017) · Scientific Reports · doi:10.1038/s41598-017-12041-y · Cited by 205
Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents
Luger, T., Amagai, M., Dreno, B., Dagnelie, M.-A., Liao, W., Kabashima, K., Schikowski, T., Proksch, E., Elias, P. M., Simon, M., et al. (2021) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2021.04.007 · Cited by 206
Self-citationNew treatments in atopic dermatitis
Puar, N., Chovatiya, R., & Paller, A. S. (2021) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2020.08.016 · Cited by 199
Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults
Silverberg, J. I., Gelfand, J. M., Margolis, D. J., Boguniewicz, M., Fonacier, L., Grayson, M. H., Ong, P. Y., Chiesa Fuxench, Z. C., & Simpson, E. L. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17683 · Cited by 199
Self-citationDupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma
Corren, J., Castro, M., O'Riordan, T., Hanania, N. A., Pavord, I. D., Quirce, S., Chipps, B. E., Wenzel, S. E., Thangavelu, K., Rice, M. S., et al. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.08.050 · Cited by 203
Self-citationBrunner, P. M., Pavel, A. B., Khattri, S., Leonard, A., Malik, K., Rose, S., Jim On, S., Vekaria, A. S., Traidl-Hoffmann, C., Singer, G. K., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.07.028 · Cited by 201
“clearance (Psoriasis Area and Severity Index [PASI90] responses) with single IL-23 cytokine antagonism,(9) only approximately 30% of patients with AD receiving dupilumab achieve a 90% reduction in their Eczema Area and Severity Index (EASI90).(8) Thus other pathways beyond the TH2 axis may play an important role in AD.”
Self-citationDavidson, W. F., Leung, D. Y. M., Beck, L. A., Berin, C. M., Boguniewicz, M., Busse, W. W., Chatila, T. A., Geha, R. S., Gern, J. E., Guttman-Yassky, E., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.01.003 · Cited by 200
“Targeted sequencing of regions of the bacterial 16S ribosomal RNA gene has highlighted the notable changes in skin microbes in patients with AD, specifically demonstrating reduced bacterial diversity in combination with shifts in the relative abundances of both S aureus and Staphylococcus epidermidis during disease fl…”
BackgroundInfluentialSelf-citationT cell pathology in skin inflammation
Sabat, R., Wolk, K., Loyal, L., Döcke, W.-D., & Ghoreschi, K. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00742-7 · Cited by 201
“More recently, the first biologic for treating atopic dermatitis, namely dupilumab, was introduced [103].”
BackgroundBangert, C., Rindler, K., Krausgruber, T., Alkon, N., Thaler, F. M., Kurz, H., Ayub, T., Demirtas, D., Fortelny, N., Vorstandlechner, V., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abe2749 · Cited by 196
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis
LaMarche, N. M., Hegde, S., Park, M. D., Maier, B. B., Troncoso, L., Le Berichel, J., Hamon, P., Belabed, M., Mattiuz, R., Hennequin, C., et al. (2024) · Nature · doi:10.1038/s41586-023-06797-9 · Cited by 197
Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases
Kolkhir, P., Elieh-Ali-Komi, D., Metz, M., Siebenhaar, F., & Maurer, M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00622-y · Cited by 193
Neuroimmune communication regulating pruritus in atopic dermatitis
Steinhoff, M., Ahmad, F., Pandey, A., Datsi, A., AlHammadi, A., Al-Khawaga, S., Al-Malki, A., Meng, J., Alam, M., & Buddenkotte, J. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.03.010 · Cited by 190
Modulating Th2 Cell Immunity for the Treatment of Asthma
León, B., & Ballesteros-Tato, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637948 · Cited by 193
Therapeutic pipeline for atopic dermatitis: End of the drought?
Paller, A. S., Kabashima, K., & Bieber, T. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.006 · Cited by 192
Self-citationDupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Hamilton, J. D., Harel, S., Swanson, B. N., Brian, W., Chen, Z., Rice, M. S., Amin, N., Ardeleanu, M., Radin, A., Shumel, B., et al. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13954 · Cited by 192
Self-citationBoguniewicz, M., Alexis, A. F., Beck, L. A., Block, J., Eichenfield, L. F., Fonacier, L., Guttman-Yassky, E., Paller, A. S., Pariser, D., Silverberg, J. I., et al. (2017) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.08.005 · Cited by 191
Self-citationThaçi, D., L. Simpson, E., Deleuran, M., Kataoka, Y., Chen, Z., Gadkari, A., Eckert, L., Akinlade, B., Graham, N. M. H., Pirozzi, G., et al. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.02.002 · Cited by 188
Self-citationGuttman-Yassky, E., Diaz, A., Pavel, A. B., Fernandes, M., Lefferdink, R., Erickson, T., Canter, T., Rangel, S., Peng, X., Li, R., et al. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.2983 · Cited by 185
Self-citationGuttman-Yassky, E., Simpson, E. L., Reich, K., Kabashima, K., Igawa, K., Suzuki, T., Mano, H., Matsui, T., Esfandiari, E., & Furue, M. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02037-2 · Cited by 187
Self-citationRerknimitr, P., Otsuka, A., Nakashima, C., & Kabashima, K. (2017) · Inflammation and Regeneration · doi:10.1186/s41232-017-0044-7 · Cited by 187
“Moreover, a recent phase III study has confirmed the findings in a larger number of patients [184].”
ResultInfectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E., Gedye, C., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 187
The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis
Otsuka, A., Nomura, T., Rerknimitr, P., Seidel, J. A., Honda, T., & Kabashima, K. (2017) · Immunological Reviews · doi:10.1111/imr.12545 · Cited by 185
Simpson, E., Bissonnette, R., Eichenfield, L. F., Guttman-Yassky, E., King, B., Silverberg, J. I., Beck, L. A., Bieber, T., Reich, K., Kabashima, K., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.104 · Cited by 183
“Reliability testing of the vIGA-AD scale and survey content Web-based surveys were developed to assess the reliability of the vIGA-AD.”
MethodInfluentialSelf-citationInfections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
Eichenfield, L. F., Bieber, T., Beck, L. A., Simpson, E. L., Thaçi, D., de Bruin-Weller, M., Deleuran, M., Silverberg, J. I., Ferrandiz, C., Fölster-Holst, R., et al. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00445-7 · Cited by 184
Self-citationJonstam, K., Swanson, B. N., Mannent, L. P., Cardell, L., Tian, N., Wang, Y., Zhang, D., Fan, C., Holtappels, G., Hamilton, J. D., et al. (2019) · Allergy · doi:10.1111/all.13685 · Cited by 181
Self-citationAtopic Eczema in Adulthood and Risk of Depression and Anxiety: A Population-Based Cohort Study
Schonmann, Y., Mansfield, K. E., Hayes, J. F., Abuabara, K., Roberts, A., Smeeth, L., & Langan, S. M. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.08.030 · Cited by 179
Wollenberg, A., Ariens, L., Thurau, S., van Luijk, C., Seegräber, M., & de Bruin-Weller, M. (2018) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.01.034 · Cited by 180
Self-citationEndotype-driven treatment in chronic upper airway diseases
De Greve, G., Hellings, P. W., Fokkens, W. J., Pugin, B., Steelant, B., & Seys, S. F. (2017) · Clinical and Translational Allergy · doi:10.1186/s13601-017-0157-8 · Cited by 179
“It has been proven to be effective in the treatment of atopic dermatitis and asthma, in which it also improved sinonasal symptoms [92, 93].”
BackgroundKapur, S., Watson, W., & Carr, S. (2018) · Allergy, Asthma & Clinical Immunology · doi:10.1186/s13223-018-0281-6 · Cited by 175
“Two phase 3 trials found dupilumab to significantly improve symptoms and quality of life in patients with AD compared to placebo [39].”
BackgroundDupilumab: First Global Approval
Shirley, M. (2017) · Drugs · doi:10.1007/s40265-017-0768-3 · Cited by 175
“In each of the three trials, adult patients (aged C18 years) with moderate-to-severe atopic dermatitis not adequately controlled by topical medication(s) were randomized (1:1:1 in SOLO 1 and SOLO 2; 3:1:3 in CHRONOS) to receive subcutaneous dupilumab 300 mg once weekly, dupilumab 300 mg once every 2 weeks or placebo […”
BackgroundResultInfluentialNeuroimmune interactions in chronic itch of atopic dermatitis
Yosipovitch, G., Berger, T., & Fassett, M. S. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15973 · Cited by 173
Classification of human chronic inflammatory skin disease based on single-cell immune profiling
Liu, Y., Wang, H., Taylor, M., Cook, C., Martínez-Berdeja, A., North, J. P., Harirchian, P., Hailer, A. A., Zhao, Z., Ghadially, R., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl9165 · Cited by 169
Maurer, M., Casale, T. B., Saini, S. S., Ben-Shoshan, M., Giménez-Arnau, A. M., Bernstein, J. A., Yagami, A., Stjepanovic, A., Radin, A., Staudinger, H. W., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.01.028 · Cited by 169
Self-citationChu, A. W. L., Wong, M. M., Rayner, D. G., Guyatt, G. H., Díaz Martinez, J. P., Ceccacci, R., Zhao, I. X., McMullen, E., Srivastava, A., Wang, J., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.08.029 · Cited by 168
Self-citationTargeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors
Welsch, K., Holstein, J., Laurence, A., & Ghoreschi, K. (2017) · European Journal of Immunology · doi:10.1002/eji.201646680 · Cited by 168
Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis
Walsh, C. M., Hill, R. Z., Schwendinger-Schreck, J., Deguine, J., Brock, E. C., Kucirek, N., Rifi, Z., Wei, J., Gronert, K., Brem, R. B., et al. (2019) · eLife · doi:10.7554/elife.48448 · Cited by 166
Immunologic, microbial, and epithelial interactions in atopic dermatitis
Brunner, P. M., Leung, D. Y. M., & Guttman-Yassky, E. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2017.09.055 · Cited by 165
Self-citationMoyle, M., Cevikbas, F., Harden, J. L., & Guttman‐Yassky, E. (2019) · Experimental Dermatology · doi:10.1111/exd.13911 · Cited by 163
Self-citationThijs, J. L., Strickland, I., Bruijnzeel-Koomen, C. A. F. M., Nierkens, S., Giovannone, B., Csomor, E., Sellman, B. R., Mustelin, T., Sleeman, M. A., de Bruin-Weller, M. S., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.03.023 · Cited by 163
Davis, D. M. R., Drucker, A. M., Alikhan, A., Bercovitch, L., Cohen, D. E., Darr, J. M., Eichenfield, L. F., Frazer-Green, L., Paller, A. S., Silverberg, J. I., et al. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.01.009 · Cited by 162
Self-citationSystemic Treatment of Adult Atopic Dermatitis: A Review
Megna, M., Napolitano, M., Patruno, C., Villani, A., Balato, A., Monfrecola, G., Ayala, F., & Balato, N. (2017) · Dermatology and Therapy · doi:10.1007/s13555-016-0170-1 · Cited by 159
“improvement in the serum levels of Th2-associated biomarkers, such as thymus and activation-regulated chemokine (TARC), total IgE and eosinophil counts [136] and by the improvement of the AD molecular signature tested with transcriptomic analyses of pre- and post-treatment skin biopsy specimens from patients with mode…”
BackgroundDrucker, A. M., Ellis, A. G., Bohdanowicz, M., Mashayekhi, S., Yiu, Z. Z. N., Rochwerg, B., Di Giorgio, S., Arents, B. W. M., Burton, T., Spuls, P. I., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.0796 · Cited by 159
Facial and neck erythema associated with dupilumab treatment: A systematic review
Jo, C. E., Finstad, A., Georgakopoulos, J. R., Piguet, V., Yeung, J., & Drucker, A. M. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.01.012 · Cited by 160
Atopic dermatitis phenotypes and the need for personalized medicine
Cabanillas, B., Brehler, A.-C., & Novak, N. (2017) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0000000000000376 · Cited by 155
Furue, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113741 · Cited by 168
Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients
Guttman‐Yassky, E., Renert‐Yuval, Y., Bares, J., Chima, M., Hawkes, J. E., Gilleaudeau, P., Sullivan-Whalen, M. M., Singer, G., Garcet, S., Pavel, A. B., et al. (2021) · Allergy · doi:10.1111/all.15071 · Cited by 176
Self-citationAriëns, L. F. M., van der Schaft, J., Bakker, D. S., Balak, D., Romeijn, M. L. E., Kouwenhoven, T., Kamsteeg, M., Giovannone, B., Drylewicz, J., van Amerongen, C. C. A., et al. (2020) · Allergy · doi:10.1111/all.14080 · Cited by 153
Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis
Thyssen, J. P., Toft, P. B., Halling, A., Gislason, G., Skov, L., & Egeberg, A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.03.003 · Cited by 170
Sensory TRP channels contribute differentially to skin inflammation and persistent itch
Feng, J., Yang, P., Mack, M. R., Dryn, D., Luo, J., Gong, X., Liu, S., Oetjen, L. K., Zholos, A. V., Mei, Z., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01056-8 · Cited by 149
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma
Weinstein, S. F., Katial, R. K., Jayawardena, S., Pirozzi, G., Staudinger, H. W., Eckert, L., Joish, V. N., Amin, N., Maroni, J. M., Rowe, P., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.11.051 · Cited by 155
Self-citationIL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases
Murdaca, G., Greco, M., Tonacci, A., Negrini, S., Borro, M., Puppo, F., & Gangemi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235856 · Cited by 161
“On this basis, dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, entered the market with great success [61].”
BackgroundCork, M. J., Thaçi, D., Eichenfield, L. F., Arkwright, P. D., Hultsch, T., Davis, J. D., Zhang, Y., Zhu, X., Chen, Z., Li, M., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18476 · Cited by 154
Self-citationBiologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect
Ratchataswan, T., Banzon, T. M., Thyssen, J. P., Weidinger, S., Guttman‐Yassky, E., & Phipatanakul, W. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.11.034 · Cited by 160
“(37) Efficacy and safety of dupilumab for treatment of AD has been studied in several phase 3 clinical trials, including SOLO-1, SOLO-2,(32) LIBERTY AD CHRONOS,(38) and AD-1526.”
BackgroundMethodInfluentialSelf-citationZhou, L., Leonard, A., Pavel, A. B., Malik, K., Raja, A., Glickman, J., Estrada, Y. D., Peng, X., del Duca, E., Sanz-Cabanillas, J., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.01.015 · Cited by 146
Self-citationIntersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma
Peters, M. C., & Wenzel, S. E. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33005-3 · Cited by 165
IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Ackerman, L., Acloque, G., Bacchelli, S., Schwartz, H., Feinstein, B. J., Stella, P. L., Alavi, A., Gollerkeri, A. M., Davis, J., Campbell, V., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02635-7 · Cited by 156
“…and JAK inhibitors) and AD (for example, cytokine-targeting antibodies and JAK inhibitors) have shown improvement in skin lesions and symptoms as early as 4 weeks into treatment 39–44 , we explored the clinical activity of KT-474 administered to patients for 4 weeks as part of the phase 1 study.”
Periostin: An emerging biomarker for allergic diseases
Izuhara, K., Nunomura, S., Nanri, Y., Ono, J., Takai, M., & Kawaguchi, A. (2019) · Allergy · doi:10.1111/all.13814 · Cited by 149
Wollenberg, A., Beck, L. A., Blauvelt, A., Simpson, E. L., Chen, Z., Chen, Q., Shumel, B., Khokhar, F. A., Hultsch, T., Rizova, E., et al. (2020) · British Journal of Dermatology · doi:10.1111/bjd.18434 · Cited by 144
Self-citationSevere Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes
Wenzel, S. E. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202009-3631ci · Cited by 166
“In contrast, dupilumab was initially FDA approved for treatment of atopic dermatitis, suggesting that signaling downstream of IL-4Ra is pathogenic, whereas downstream IgE is not (78).”
BackgroundEfficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis
Paller, A. S., Flohr, C., Cork, M. J., Bewley, A., Blauvelt, A., Hong, H., Imafuku, S., Schuttelaar, M. L. A., Simpson, E. L., Soong, W., et al. (2023) · JAMA Dermatology · doi:10.1001/jamadermatol.2023.0627 · Cited by 164
Self-citationWerfel, T., Layton, G., Yeadon, M., Whitlock, L., Osterloh, I., Jimenez, P., Liu, W., Lynch, V., Asher, A., Tsianakas, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.07.047 · Cited by 139
Blauvelt, A., Simpson, E. L., Tyring, S. K., Purcell, L. A., Shumel, B. S., Petro, C. D., Akinlade, B. K., Gadkari, A. S., Eckert, L., Graham, N. M. H., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.07.048 · Cited by 145
Self-citationBeck, L. A., Thaçi, D., Deleuran, M. S., Blauvelt, A., Bissonnette, R., de Bruin-Weller, M. S., Hide, M., Sher, L., Hussain, I., Chen, Z., et al. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00527-x · Cited by 144
Self-citationA contemporary look at allergic conjunctivitis
Dupuis, P., Prokopich, C. L., Hynes, A. P., & Kim, H. L. (2020) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-020-0403-9 · Cited by 166
New and Emerging Systemic Treatments for Atopic Dermatitis
Newsom, M., Bashyam, A. M., Balogh, E. A., Feldman, S. R., & Strowd, L. C. (2020) · Drugs · doi:10.1007/s40265-020-01335-7 · Cited by 136
He, H., Olesen, C. M., Pavel, A. B., Clausen, M., Wu, J., Estrada, Y. D., Zhang, N., Agner, T., & Guttman‐Yassky, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01768 · Cited by 146
Self-citationAdverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis
Ou, Z., Chen, C., Chen, A., Yao, Y., & Zhou, W. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.11.031 · Cited by 143
Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis
Treister, A. D., Kraff-Cooper, C., & Lio, P. A. (2018) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.2690 · Cited by 135
Dupin, C., Belhadi, D., Guilleminault, L., Gamez, A. S., Berger, P., Frederic de, B. L. A. Y., Bonniaud, P., Leroyer, C., Mahay, G., Girodet, P., et al. (2020) · Clinical & Experimental Allergy · doi:10.1111/cea.13614 · Cited by 143
“During the 12 months before the first injection of dupilumab, the median exacerbation rate was 4 [3-9] exacerbations, and 28/58 (48%) patients had been hospitalized at least once for asthma.”
BackgroundResultInfluentialRole of AHR Ligands in Skin Homeostasis and Cutaneous Inflammation
Fernández-Gallego, N., Sánchez-Madrid, F., & Cibrian, D. (2021) · Cells · doi:10.3390/cells10113176 · Cited by 133
“Although they are treatable using biological therapies aimed at blocking IL-4/IL-13 in AD [4], and TNF-α/IL-23/IL17 in PS [5,6], both conditions remain uncured, and their frequent relapse episodes deteriorate the quality of life of the patients.”
BackgroundThe IL‐13/periostin/IL‐24 pathway causes epidermal barrier dysfunction in allergic skin inflammation
Mitamura, Y., Nunomura, S., Nanri, Y., Ogawa, M., Yoshihara, T., Masuoka, M., Tsuji, G., Nakahara, T., Hashimoto‐Hachiya, A., Conway, S. J., et al. (2018) · Allergy · doi:10.1111/all.13437 · Cited by 130
“Based on the underlying mechanism of AD, various molecularly targeted drugs against proinflammatory cytokines have been developed, among which the antibodies against the IL-4Ra chain shared by both IL-4R and IL-13R (dupilumab) and the inhibitor against JAK (tofacitinib), particularly JAK1 and JAK3, have shown good eff…”
BackgroundAssociation Between Atopic Dermatitis and Suicidality: A Systematic Review and Meta-analysis
Sandhu, J. K., Wu, K. C. ‐., Bui, T., & Armstrong, A. W. (2018) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.4566 · Cited by 156
Bissonnette, R., Maari, C., Forman, S., Bhatia, N., Lee, M., Fowler, J., Tyring, S., Pariser, D., Sofen, H., Dhawan, S., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17932 · Cited by 130
Self-citationBlauvelt, A., Guttman‐Yassky, E., Paller, A. S., Simpson, E. L., Cork, M. J., Weisman, J. D., Browning, J., Soong, W., Sun, X., Chen, Z., et al. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00683-2 · Cited by 150
Self-citationFleming, P., & Drucker, A. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.09.052 · Cited by 136
Itch: A Paradigm of Neuroimmune Crosstalk
Wang, F., & Kim, B. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.008 · Cited by 129
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results
Silverberg, J. I., de Bruin-Weller, M. S., Bieber, T. R. M., Soong, W., Kabashima, K., Costanzo, A., Rosmarin, D. M., Lynde, C. W., Liu, J., Gamelli, A., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.07.036 · Cited by 139
Self-citationLocal allergic rhinitis: Implications for management
Campo, P., Eguíluz‐Gracia, I., Bogas, G., Salas, M. L., Serón, C. P., Pérez, N., Mayorga, C., Torres, M. J., Shamji, M. H., & Rondón, C. (2018) · Clinical & Experimental Allergy · doi:10.1111/cea.13192 · Cited by 141
Silverberg, J. I., Yosipovitch, G., Simpson, E. L., Kim, B., Wu, J. J., Eckert, L., Guillemin, I., Chen, Z., Ardeleanu, M., Bansal, A., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.02.060 · Cited by 141
Self-citationOgonowska, P., Gilaberte, Y., Barańska-Rybak, W., & Nakonieczna, J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.567090 · Cited by 127
Endophenotypic Variations of Atopic Dermatitis by Age, Race, and Ethnicity
Nomura, T., Wu, J., Kabashima, K., & Guttman-Yassky, E. (2020) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.02.022 · Cited by 128
Self-citationSleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies
Bawany, F., Northcott, C. A., Beck, L. A., & Pigeon, W. R. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.12.007 · Cited by 231
Self-citationDupilumab: A New Paradigm for the Treatment of Allergic Diseases
Sastre, J., & Davila, I. J. (2018) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0254 · Cited by 144
“It has been speculated that this increment in the frequency of conjunctivitis could limit the use of dupilumab in the treatment of allergic diseases, especially in children [77].”
BackgroundMild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities
He, H., Del Duca, E., Diaz, A., Kim, H. J., Gay-Mimbrera, J., Zhang, N., Wu, J., Beaziz, J., Estrada, Y., Krueger, J. G., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.08.041 · Cited by 126
Self-citationConfirmation of multiple endotypes in atopic dermatitis based on serum biomarkers
Bakker, D. S., Nierkens, S., Knol, E. F., Giovannone, B., Delemarre, E. M., van der Schaft, J., van Wijk, F., de Bruin-Weller, M. S., Drylewicz, J., & Thijs, J. L. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.062 · Cited by 126
Ferreira, S., Guttman‐Yassky, E., & Torres, T. R. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00548-6 · Cited by 135
Self-citationNew treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines
Renert-Yuval, Y., & Guttman-Yassky, E. (2020) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2019.10.005 · Cited by 125
Self-citationNomenclature and clinical phenotypes of atopic dermatitis
Girolomoni, G., de Bruin-Weller, M. S., Aoki, V., Kabashima, K., Deleuran, M. S., Puig, L., Bansal, A., & Rossi, A. B. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211002979 · Cited by 138
Self-citationButler, D. C., Berger, T. G., Elmariah, S. B., Kim, B., Chisolm, S., Kwatra, S. G., Mollanazar, N. K., & Yosipovitch, G. (2024) · JAMA · doi:10.1001/jama.2024.4899 · Cited by 147
Principles of inflammasome priming and inhibition: implications for psychiatric disorders
Herman, F. J., & Pasinetti, G. M. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.06.010 · Cited by 115
Engineering the IL ‐4/ IL ‐13 axis for targeted immune modulation
Bernstein, Z. J., Shenoy, A., Chen, A. Y.-C., Heller, N. M., & Spangler, J. B. (2023) · Immunological Reviews · doi:10.1111/imr.13230 · Cited by 140
Eosinophils and eosinophil-associated diseases: An update
O’Sullivan, J. A., & Bochner, B. S. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.09.022 · Cited by 141
Leveraging Multilayered “Omics” Data for Atopic Dermatitis: A Road Map to Precision Medicine
Ghosh, D., Bernstein, J. A., Khurana Hershey, G. K., Rothenberg, M. E., & Mersha, T. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02727 · Cited by 121
Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysis
Siegels, D., Heratizadeh, A., Abraham, S., Binnmyr, J., Brockow, K., Irvine, A. D., Halken, S., Mortz, C. G., Flohr, C., Schmid‐Grendelmeier, P., et al. (2020) · Allergy · doi:10.1111/all.14631 · Cited by 137
Dyjack, N., Goleva, E., Rios, C., Kim, B. E., Bin, L., Taylor, P., Bronchick, C., Hall, C. F., Richers, B. N., Seibold, M. A., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.046 · Cited by 117
Heterogeneity in the initiation, development and function of type 2 immunity
Gause, W. C., Rothlin, C., & Loke, P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0301-x · Cited by 119
Berdyshev, E., Goleva, E., Bissonnette, R., Bronova, I., Bronoff, A. S., Richers, B. N., Garcia, S., Ramirez‐Gama, M., Taylor, P., Praestgaard, A., et al. (2022) · Allergy · doi:10.1111/all.15432 · Cited by 116
Metadata
- Authors
- Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., Kingo, K., Worm, M., Poulin, Y., Wollenberg, A., Soo, Y., Graham, N. M. H., Pirozzi, G., Akinlade, B., Staudinger, H., Mastey, V., Eckert, L., Gadkari, A., Stahl, N., Yancopoulos, G. D., & Ardeleanu, M.
- Affiliations
- University of Bonn (DE)
- Northwestern University (US)
- ORCID
- Simpson, Eric L.
- Bieber, Thomas
- Beck, Lisa A.
- Blauvelt, Andrew
- Cork, Michael J.
- Silverberg, Jonathan I.
- Deleuran, Mette
- Kataoka, Yoko
- Lacour, Jean-Philippe
- Kingo, Külli
- Worm, Margitta
- Poulin, Yves
- Wollenberg, Andreas
- Soo, Yuhwen
- Graham, Neil M.H.
- Pirozzi, Gianluca
- Akinlade, Bolanle
- Staudinger, Heribert
- Eckert, Laurent
- Stahl, Neil
- Ardeleanu, Marius
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-15
- Volume
- 375
- Issue
- 24
- Pages
- 2335-2348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2524051065
- Cited by
- 2,110
- References
- 38
- Citations by year
- 2026: 183 · 2025: 219 · 2024: 227 · 2023: 239 · 2022: 218 · 2021: 238 · 2020: 244 · 2019: 236 · 2018: 160 · 2017: 130 · 2016: 8
- FWCI
- 211.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- Scopus (Elsevier) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- ab, atopic dermatitis, IL-4 receptor alpha, IL-13, IL-4, type 2 cytokines, monoclonal antibodies, subcutaneous administration, dosing frequency, Investigator's Global Assessment, Eczema Area and Severity Index, pruritus, injection site reactions, conjunctivitis, quality of life
- MeSH terms
- Adult, Anti-Inflammatory Agents, Antibodies, Monoclonal, Dermatitis, Atopic, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Nasopharyngitis, Pruritus, Quality of Life, Interleukin-4, Interleukin-13, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.